Hilton’s acquisition of Eisai pharmaceutical products approved – Business

ISLAMABAD: The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products by Tokyo-based Eisai by Hilton Pharma. The acquisition includes the rights to manufacture and commercialize Methycobal and Myonal in Pakistan.

The transaction involves the transfer of trademarks, know-how and documentation related to these products under an asset purchase agreement signed between the two companies. The purpose of this agreement is to facilitate the production and distribution of these medicines in Pakistan.

Hilton Pharma, founded in 1989, produces and distributes medicinal products in the country. The company is authorized by the Pakistan Drugs Regulatory Authority to produce pharmaceutical products.

Eisai is a global leader in pharmaceutical research, development, manufacturing and marketing, with a particular focus on prescription drugs.

Published in Dawn, June 26, 2024